Why do third-party LLMs create privacy and compliance risk for healthcare data?

Third-party LLMs create risk because PHI may leave the covered entity’s control and enter systems whose storage, retention, and training practices are not fully visible to the organization. That complicates HIPAA alignment, BAA requirements, and contractual restrictions on onward sharing. Once data is externalized, healthcare teams may lose meaningful assurance over how it is handled or reused.

Why third-party LLMs become a privacy boundary problem

Third-party LLMs are not just another software tool, they are an external processing environment. When healthcare teams send prompts, records, or snippets of clinical context to a vendor-hosted model, they often lose direct control over where the data is stored, what retention applies, and who can inspect it. For PHI, that boundary matters because privacy risk is created as soon as the data leaves the organization’s governed environment.

That risk is not limited to obvious uploads. It can also arise through logs, support workflows, telemetry, prompt history, model improvement programs, and cross-tenant handling. In practice, the question is not only whether the vendor is reputable, but whether the organization can prove the data path, the retention path, and the access path end to end.

Healthcare teams should treat the external model as a separate processing domain, not a neutral extension of internal chat. If the workflow cannot answer where PHI lands after submission, the privacy boundary is already weaker than most compliance programs assume.

How compliance exposure shows up under HIPAA and contracts

Compliance risk appears when the organization cannot align the LLM workflow with its HIPAA obligations, its business associate agreements, and its own contract terms for onward use. A third-party LLM may be fine for de-identified or low-risk content, but once PHI is in scope, the vendor’s handling practices become part of the compliance problem, not just the technical stack.

That creates several common failure points: sending PHI to a service without an adequate BAA, allowing prompts to be retained longer than policy permits, or permitting model training or human review where the contract was meant to prohibit it. Even when the vendor’s default posture is acceptable, organizations can still create noncompliance by misconfiguring the integration, expanding use cases without review, or failing to classify the data being sent.

Privacy and compliance controls need to be evaluated together here. A workflow can be technically convenient and still fail because the organization cannot demonstrate lawful processing, purpose limitation, minimization, or vendor accountability. For healthcare data, that burden does not disappear just because the data is processed by a model rather than a person.

What matters most in vendor selection and deployment

The most important control question is whether the healthcare organization can constrain the LLM enough to make its use case auditable. That means reviewing the vendor’s retention settings, training exclusions, region handling, encryption posture, admin access model, and contractual commitments before allowing PHI into the system. It also means checking whether the product keeps customer data isolated from other tenants and whether any human support access is tightly governed.

Independent guidance on data protection is useful here. The NIST Privacy Framework is a good fit for mapping data governance and privacy risk decisions, while the GDPR is a reminder that data protection by design, security of processing, and DPIA-style thinking matter when sensitive personal data is processed externally. For healthcare vendors, SOC 2 Trust Services Criteria can help frame expectations around confidentiality and privacy controls, although it does not replace HIPAA obligations.

Where the model is used for enterprise workflows, the vendor relationship itself becomes a control surface. If the organization cannot review or evidence the vendor’s retention, subprocessor, and access practices, the deployment should be treated as higher risk until those gaps are closed.

Risk and Threat Considerations

Third-party LLMs increase exposure because sensitive healthcare content can spread into logs, backups, support channels, and model-training pathways that the covered entity does not fully control. The main risk is loss of visibility and enforceability over PHI after it crosses the boundary.

Failure mechanism: The organization sends PHI to an external processor without tight contractual, technical, and administrative constraints, so retention or reuse occurs outside the intended compliance model.

Impact: That can create unauthorized disclosure, unlawful processing, audit failure, and remediation costs if the organization cannot show how the data was handled or prevent further spread.

Standards & Framework Alignment

This section maps relevant standards and security frameworks to the operational risks and controls described in this guidance.

NIST SP 800-53 Rev 5 sets the technical controls, while GDPR and SOC 2 (AICPA) define the regulatory obligations.

Framework	Control / Reference	Relevance
NIST SP 800-53 Rev 5	AC-21 — Information Sharing	Covers controlling what sensitive health data is shared with external processors.
	AU-2 — Event Logging	Relevant because vendor logging and prompt history can expose PHI handling paths.
	PL-8 — Information Security and Privacy Architecture	Applies to designing data boundaries for external AI processing.
Recommendation — Restrict PHI sharing to approved external services and document the allowed data flows. Define what LLM interactions are logged and ensure logs exclude unnecessary PHI. Map PHI flows and vendor trust boundaries into the privacy architecture before deployment.
GDPR	Article 5 — Principles relating to processing of personal data	Directly supports minimization, purpose limitation, and storage limitation concerns for healthcare data.
	Article 25 — Data protection by design and by default	Applies when external LLM workflows must embed privacy controls up front.
Recommendation — Minimize personal data sent to third-party LLMs and limit retention to the stated purpose. Build privacy controls into the LLM workflow before any PHI is enabled.
SOC 2 (AICPA)	CC6.1 — Logical and Physical Access Controls	Relevant to vendor access restrictions over sensitive healthcare data and supporting systems.
	CC8.1 — Change Management	Supports controlled changes to vendor retention, training, or sharing behavior.
Recommendation — Confirm the provider limits who can access prompt data, outputs, and related logs. Require review before any vendor change can expand data retention or reuse.

Practitioner Guidance

What to verify: Before approving a third-party LLM for healthcare data, verify the exact data elements allowed, whether PHI is excluded or permitted, how long prompts and outputs are retained, and whether training or human review is disabled by contract and configuration.

Decision rule: If the team cannot explain the data flow to the vendor in one paragraph, it is not ready for PHI. Treat unknown retention, unclear onward use, or missing BAA coverage as a stop condition, not a documentation issue to fix later.

Practitioner takeaway: The core problem is not that an LLM is external, it is that once PHI leaves controlled systems, compliance depends on vendor behavior the healthcare team may no longer be able to observe, limit, or evidence.